Literature DB >> 6819599

Treatment of status epilepticus with intravenous clonazepam.

A N Singh, P Le Morvan.   

Abstract

1. Intravenous clonazepam was investigated in an open trial conducted in 24 patients suffering from status epilepticus. 2. The administration of 1-2 mg clonazepam resulted in the complete control of 7/7 Petit Mal, 7/14 Grand Mal and 2/3 partial complex cases. 3. The mean time to obtain clinical control of seizures after injection was 1.75 min. In all successfully treated cases normalization or improvement of the post-ictal EEG tracing was observed. 4. Vital signs measured before and immediately after clonazepam injections showed no clinically significant changes in blood pressure, heart rate or respiration. Side effects consisted exclusively of transient mild to moderate drowsiness in 40% of patients. 5. These results indicate that intravenous clonazepam is rapidly effective and safe in the treatment of Petit Mal status and in certain cases of Grand Mal and partial complex status epilepticus. This agent therefore represents a useful alternative to diazepam in the treatment of status epilepticus.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6819599     DOI: 10.1016/s0278-5846(82)80146-2

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  3 in total

1.  Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: A multicenter comparison.

Authors:  Vincent Alvarez; Jong Woo Lee; Frank W Drislane; M Brandon Westover; Jan Novy; Barbara A Dworetzky; Andrea O Rossetti
Journal:  Epilepsia       Date:  2015-07-03       Impact factor: 5.864

Review 2.  Pharmacotherapy for Status Epilepticus.

Authors:  Eugen Trinka; Julia Höfler; Markus Leitinger; Francesco Brigo
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

Review 3.  Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability.

Authors:  Adam Strzelczyk; Laurent M Willems; Ricardo Kienitz; Lara Kay; Isabelle Beuchat; Sarah Gelhard; Sophie von Brauchitsch; Catrin Mann; Alexandra Lucaciu; Jan-Hendrik Schäfer; Kai Siebenbrodt; Johann-Philipp Zöllner; Susanne Schubert-Bast; Felix Rosenow
Journal:  CNS Drugs       Date:  2022-08-16       Impact factor: 6.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.